Schering AG To Continue Leukine Development In Wake Of Phase III Crohn’s Failure
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Schering AG will continue clinical development of Leukine for Crohn's disease despite disappointing results from a Phase III induction trial